Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics
GET POWR RATINGS... FREE!
RDY POWR Grades
- Stability is the dimension where RDY ranks best; there it ranks ahead of 89.42% of US stocks.
- RDY's strongest trending metric is Stability; it's been moving down over the last 179 days.
- RDY ranks lowest in Momentum; there it ranks in the 8th percentile.
RDY Stock Summary
- RDY's current price/earnings ratio is 2,975.43, which is higher than 99.74% of US stocks with positive earnings.
- With a price/sales ratio of 270.7, Dr Reddys Laboratories Ltd has a higher such ratio than 98.77% of stocks in our set.
- Revenue growth over the past 12 months for Dr Reddys Laboratories Ltd comes in at -98.4%, a number that bests only 0.78% of the US stocks we're tracking.
- Stocks that are quantitatively similar to RDY, based on their financial statements, market capitalization, and price volatility, are APPF, TARO, NXGN, FREE, and ICCC.
- RDY's SEC filings can be seen here. And to visit Dr Reddys Laboratories Ltd's official web site, go to www.drreddys.com.
RDY Stock Price Chart Interactive Chart >
RDY Price/Volume Stats
| Current price | $55.36 | 52-week high | $75.50 |
| Prev. close | $55.39 | 52-week low | $47.88 |
| Day low | $55.01 | Volume | 21,417 |
| Day high | $55.47 | Avg. volume | 193,158 |
| 50-day MA | $53.85 | Dividend yield | 0.51% |
| 200-day MA | $58.47 | Market Cap | 9.21B |
Dr. Reddy's Laboratories Ltd (RDY) Company Bio
Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.
Latest RDY News From Around the Web
Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.
''Mankind Pharma'' To Acquire Two Brands From Dr Reddy''s LaboratoriesMankind Pharma on Wednesday said it has inked a pact with Dr Reddy''s Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising |
Mankind Pharma to acquire 2 brands from DRLMankind Pharma on Wednesday said it has inked a pact with Dr Reddy''s Laboratories to acquire two brands -- Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising bar for infants. Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent. |
Dr Reddy inks exclusive commercial agreements with Novartis for select brandsDr Reddy''S Laboratories has entered into an exclusive sales and distribution agreement with Novartis India (NIL) for the Voveran range, the calcium range and Methergine in India. |
Novartis India signs sales and distribution pact with Dr Reddy''s Laboratories; to lay off 400 employeesNovartis India has signed an exclusive sales and distribution pact with Dr Reddys Laboratories for a few of its medicines |
Dr Reddy''s inks exclusive sales pact with Novartis IndiaDr Reddy''s Laboratories has entered into an exclusive sales and distribution agreement with Novartis India Ltd (NIL), a statement said on Friday. However, this will also lead to around 400 NIL employees being laid off due to role redundancies. Under the arrangement, Dr Reddy''s will have exclusive rights to promote and distribute the well-established Voveran range, the Calcium range and Methergine in India. The company will use its strengths in promotion and distribution to considerably expand its engagement with healthcare professionals with the aim of enabling access to patients in need. "We are delighted to enter into this arrangement with NIL to promote and distribute these well-established brands that are trusted by patients and healthcare professionals," Dr Reddy''s Laboratories ... |
RDY Price Returns
| 1-mo | 0.16% |
| 3-mo | -0.82% |
| 6-mo | -15.36% |
| 1-year | -25.76% |
| 3-year | 49.87% |
| 5-year | 36.10% |
| YTD | -15.36% |
| 2021 | -7.49% |
| 2020 | 76.61% |
| 2019 | 8.38% |
| 2018 | 1.18% |
| 2017 | -16.47% |
RDY Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching RDY
Want to do more research on Dr Reddys Laboratories Ltd's stock and its price? Try the links below:Dr Reddys Laboratories Ltd (RDY) Stock Price | Nasdaq
Dr Reddys Laboratories Ltd (RDY) Stock Quote, History and News - Yahoo Finance
Dr Reddys Laboratories Ltd (RDY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...